Berberine vs Semaglutide: Which Is Better for Weight Loss?
No. Berberine scores 6.8 and semaglutide 6.0, and that gap misleads almost everyone who reads it. Berberine scores higher because it is cheap, oral and easy to stop,…
- Berberine
- Semaglutide
Every intervention Outliyr has scored for kidney health, ranked by its BioHarmony score for this use case rather than its overall rating. The number beside each name is how well that one thing works for kidney health; the tier beside it is what it is worth once safety, cost and effort are counted across everything else.
21 of 75 evaluated interventions score 3.0+ out of 10 for kidney health · 4 comparisons
Kidney-function reaches 7.0/10 because Perkovic 2024 found 24% lower major kidney disease or death composite risk in type 2 diabetes with CKD. That is a meaningful clinical endpoint, not a wellness proxy.…
Read the Semaglutide report →For readers tracking kidney function, Senolytics deserves 6.0/10 because Justice et al. 2019 gives the strongest anchor. Hickson 2019 reported D+Q senescence-marker reductions in diabetic kidney disease, but it was small, preliminary,…
Read the Senolytics report →Kidney relevance is most credible in type 2 diabetes and cardiometabolic risk. Weight, glucose, blood pressure, and albuminuria risk factors all improve. SURPASS CVOT improved some kidney metrics versus dulaglutide. The primary…
Read the Tirzepatide report →Glycine kidney function earns 5.5/10 because Soh 2024 anchors the most relevant signal. Glycine fits kidney function because glycine participates in sleep signaling, glutathione, collagen, methylation, and nervous-system balance, depending on the…
Read the Glycine report →The kidney-function case for Ca-AKG (Calcium Alpha-Ketoglutarate) is 5.4/10 because Filip 2007 gives the most relevant evidence anchor. The existing rationale points to this narrower claim: the cited study hemodialysis literature supports…
Read the Ca-AKG (Calcium Alpha-Ketoglutarate) report →The preclinical data give SLU-PP-332 a kidney-function score of 5.0 out of 10, based on the mouse study by Wang et al. 2023. Wang et al. 2023 reported that ERR agonism reversed…
Read the SLU-PP-332 report →Higher fitness and better blood pressure control are relevant to kidney-risk reduction, but Zone 2 is not a kidney-specific therapy. CKD patients should individualize intensity, hydration, blood pressure monitoring, and medication timing…
Read the Zone 2 Cardio report →Healthy kidneys handle typical EAA doses, but CKD stage 4-5 requires clinician supervision because nitrogen handling matters. This use case is a caution area, not a benefit claim.
Read the Essential Amino Acids report →No direct kidney-function evidence. Avoid extrapolating circulation claims into renal benefit claims.
Read the Whole-Body Vibration report →Birk 2013 showed renal ischemia protection and ATP recovery in preclinical models; no positive human renal endpoint trial was verified.
Read the SS-31 (Elamipretide) report →INSUFFICIENT_EVIDENCE for healthy kidney optimization; transplant history proves use in renal medicine but not kidney-function enhancement in healthy users.
Read the Rapamycin report →Standardized-extract trials such as Chen 2014 did not show clinically meaningful kidney-marker changes over short windows. No kidney-benefit evidence supports a higher score.
Read the Tongkat Ali report →Hickson 2019 used D plus Q in 9 diabetic kidney disease patients and reduced adipose and skin senescence markers within 11 days; clinical renal endpoints were not powered. Ferry 1996 phase 1…
Read the Quercetin report →No clear positive or negative kidney-function signal in verified human outcome data.
Read the Spermidine report →Adequate hydration supports renal function, but potassium-heavy supplementation is contraindication-sensitive in chronic kidney disease and interacting medications.
Read the Electrolytes report →Contrast-induced nephropathy prevention is the headline kidney claim, and it is settled negative: the large ACT (2011) and PRESERVE (2018) trials found NAC no better than placebo. Early small-trial enthusiasm did not…
Read the NAC (N-Acetylcysteine) report →Some small signals in CoQ10-deficiency-related nephropathy and dialysis populations, but no broad renal-outcome evidence for general use.
Read the Coenzyme Q10 (CoQ10 / Ubiquinol) report →Some animal nephroprotection data exists, but direct human renal-outcome evidence is lacking.
Read the Spirulina report →Kidney support is mechanistic only, with antioxidant protection of renal tissue but no GlyNAC-specific human outcome trial. Scores 3.0/10.
Read the GlyNAC (Glycine + N-Acetylcysteine) report →O. sinensis preparations improved markers in dialysis patients (Liu 2024 meta-analysis, low certainty), but chaga is a documented cause of oxalate kidney injury, so the net class picture is mixed and dose-dependent.
Read the Adaptogenic Mushrooms (Reishi, Cordyceps, Chaga) report →TRT is not kidney-protective. TRAVERSE raised enough kidney-safety concern to keep chronic kidney disease users in a cautious monitoring lane, especially when blood pressure, hematocrit, and edema are unstable.
Read the TRT (Testosterone Replacement Therapy) report →Nothing matches those filters.
Head-to-head reports and category rankings that name a winner on this use case.
No. Berberine scores 6.8 and semaglutide 6.0, and that gap misleads almost everyone who reads it. Berberine scores higher because it is cheap, oral and easy to stop,…
Melanotan I is the safer tanning peptide and it scores higher, 6.2 against 4.6. Both darken skin through the same receptor. Melanotan II hits three more receptors, which…
NAC scores 8.0 and glutathione 6.2, and that gap is real. NAC is the cheaper upstream precursor with a six-decade clinical record, so start there. Glutathione earns its…
Tirzepatide scores 6.1 and semaglutide 6.0, so the overall scores don't pick a winner. Your reason for taking one does. Tirzepatide wins on weight and body composition. Semaglutide…
Semaglutide, at 7.0 out of 10 for kidney health. Kidney-function reaches 7.0/10 because Perkovic 2024 found 24% lower major kidney disease or death composite risk in type 2 diabetes with CKD.
Of the top-scoring options, Glycine is the least expensive at about $2 a month, scoring 5.5 out of 10 for kidney health.
21 of the 75 interventions evaluated for kidney health score 3.0 out of 10 or better, which is the cut-off for appearing on this page.